SG194230A1 - Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders - Google Patents
Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders Download PDFInfo
- Publication number
- SG194230A1 SG194230A1 SG2013079603A SG2013079603A SG194230A1 SG 194230 A1 SG194230 A1 SG 194230A1 SG 2013079603 A SG2013079603 A SG 2013079603A SG 2013079603 A SG2013079603 A SG 2013079603A SG 194230 A1 SG194230 A1 SG 194230A1
- Authority
- SG
- Singapore
- Prior art keywords
- phenyl
- salkyl
- group
- optionally substituted
- independently
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 206010003805 Autism Diseases 0.000 title claims abstract description 47
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 47
- 208000023105 Huntington disease Diseases 0.000 title claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 72
- -1 stereoisomers Chemical class 0.000 claims description 48
- 125000001424 substituent group Chemical group 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 125000003368 amide group Chemical group 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 150000001204 N-oxides Chemical class 0.000 claims description 11
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 9
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 9
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 206010012335 Dependence Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 208000000044 Amnesia Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 5
- 230000006984 memory degeneration Effects 0.000 claims description 5
- 208000023060 memory loss Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229940127240 opiate Drugs 0.000 claims description 4
- 230000003956 synaptic plasticity Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010008027 Cerebellar atrophy Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims description 3
- 208000010496 Heart Arrest Diseases 0.000 claims description 3
- 208000030990 Impulse-control disease Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 206010028570 Myelopathy Diseases 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010008129 cerebral palsy Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 claims description 2
- 101150037123 APOE gene Proteins 0.000 claims description 2
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 2
- 101001000686 Homo sapiens 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 claims description 2
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims description 2
- 101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 claims description 2
- 102100039909 Neuronal acetylcholine receptor subunit alpha-4 Human genes 0.000 claims description 2
- 102100024622 Proenkephalin-B Human genes 0.000 claims description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 2
- 108010074732 preproenkephalin Proteins 0.000 claims description 2
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical group C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 30
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract description 15
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract description 15
- 239000004031 partial agonist Substances 0.000 abstract description 9
- 239000004471 Glycine Substances 0.000 abstract description 8
- 241000700159 Rattus Species 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 30
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000027928 long-term synaptic potentiation Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 230000000971 hippocampal effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 5
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000002787 reinforcement Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000000225 synapse Anatomy 0.000 description 5
- 230000005062 synaptic transmission Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 208000029560 autism spectrum disease Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000010149 post-hoc-test Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 3
- 229930195711 D-Serine Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 238000013289 male long evans rat Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 210000002442 prefrontal cortex Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010041243 Social avoidant behaviour Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000001176 projection neuron Anatomy 0.000 description 2
- 201000005070 reflex epilepsy Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000027765 speech disease Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 201000009010 Frontal lobe epilepsy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001030705 Homo sapiens Huntingtin Proteins 0.000 description 1
- 101001099423 Homo sapiens Proenkephalin-A Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 206010034703 Perseveration Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- 102100038931 Proenkephalin-A Human genes 0.000 description 1
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008503 anti depressant like effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 208000022804 avoidant personality disease Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 102000054185 human HTT Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000003040 photosensitive epilepsy Diseases 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479593P | 2011-04-27 | 2011-04-27 | |
| US201161527744P | 2011-08-26 | 2011-08-26 | |
| PCT/US2012/035547 WO2012149389A2 (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG194230A1 true SG194230A1 (en) | 2013-12-30 |
Family
ID=47073094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013079603A SG194230A1 (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| SG10202010665YA SG10202010665YA (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010665YA SG10202010665YA (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140107037A1 (enExample) |
| EP (2) | EP3679931A3 (enExample) |
| JP (1) | JP6035326B2 (enExample) |
| KR (5) | KR20210046843A (enExample) |
| CN (2) | CN108283712A (enExample) |
| AU (1) | AU2012249397B2 (enExample) |
| BR (1) | BR112013027554A2 (enExample) |
| CA (1) | CA2834286A1 (enExample) |
| EA (2) | EA029999B1 (enExample) |
| HK (1) | HK1258231A1 (enExample) |
| MX (1) | MX357761B (enExample) |
| SG (2) | SG194230A1 (enExample) |
| WO (1) | WO2012149389A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Ｎｍｄａ 수용체 조절제 및 그의 용도 |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| CA2789331C (en) | 2010-02-11 | 2017-11-07 | Northwestern University | Secondary structure stabilized nmda receptor modulators and uses thereof |
| BR112015018087B1 (pt) | 2013-01-29 | 2022-09-20 | Aptinyx Inc | Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos |
| JP6531042B2 (ja) | 2013-01-29 | 2019-06-12 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| CA2899010A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20151436A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| MX2015009773A (es) | 2013-01-29 | 2016-08-05 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| EP3062810A4 (en) * | 2013-10-28 | 2017-05-03 | Naurex Inc. | Nmda receptor modulators and prodrugs, salts, and uses thereof |
| EP3721799A1 (en) * | 2013-12-13 | 2020-10-14 | Northwestern University | Methods of treating brain disorders or identifying biomarkers related thereto |
| CN105327349A (zh) * | 2014-06-18 | 2016-02-17 | 上海翰森生物医药科技有限公司 | Nmda受体拮抗剂的医药用途及其药物组合物 |
| WO2015200322A1 (en) * | 2014-06-23 | 2015-12-30 | Northwestern University | Methods of treating or ameliorating migraine |
| CN108601814A (zh) * | 2015-10-16 | 2018-09-28 | 西北大学 | 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合 |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20190174A1 (es) | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| CN109661398B (zh) | 2016-08-01 | 2022-07-05 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途 |
| US10918637B2 (en) | 2016-08-01 | 2021-02-16 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| AU2017306152A1 (en) | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| SG11201900554YA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda modulators and methods of using same |
| BR112019001921A2 (pt) | 2016-08-01 | 2019-05-14 | Aptinyx Inc. | moduladores do receptor nmda de espiro-lactama e seus usos |
| US11578072B2 (en) | 2018-01-31 | 2023-02-14 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| KR102415692B1 (ko) | 2020-09-01 | 2022-07-05 | 건국대학교 글로컬산학협력단 | 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| GB0018272D0 (en) * | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| US20060167032A1 (en) * | 2002-01-16 | 2006-07-27 | Galer Bradley S | Pharmaceutical composition and method for treating disorders of the central nervous system |
| US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| PT2030622E (pt) * | 2005-03-24 | 2011-06-02 | Univ Emory | Indicação da dose de progesterona no tratamento de um traumatismo crânio-encefálico |
| CA2716375C (en) * | 2008-02-20 | 2018-05-29 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
| KR101769999B1 (ko) * | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Ｎｍｄａ 수용체 조절제 및 그의 용도 |
| PL2485751T3 (pl) * | 2009-10-05 | 2014-10-31 | Univ Northwestern | GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie |
-
2012
- 2012-04-27 SG SG2013079603A patent/SG194230A1/en unknown
- 2012-04-27 JP JP2014508130A patent/JP6035326B2/ja not_active Expired - Fee Related
- 2012-04-27 MX MX2013012526A patent/MX357761B/es active IP Right Grant
- 2012-04-27 EA EA201391581A patent/EA029999B1/ru unknown
- 2012-04-27 EA EA201790653A patent/EA201790653A1/ru unknown
- 2012-04-27 EP EP20151676.2A patent/EP3679931A3/en not_active Withdrawn
- 2012-04-27 KR KR1020217011613A patent/KR20210046843A/ko not_active Ceased
- 2012-04-27 EP EP12777016.2A patent/EP2701721A4/en not_active Ceased
- 2012-04-27 CN CN201711451914.XA patent/CN108283712A/zh active Pending
- 2012-04-27 CA CA2834286A patent/CA2834286A1/en not_active Abandoned
- 2012-04-27 SG SG10202010665YA patent/SG10202010665YA/en unknown
- 2012-04-27 KR KR1020187022910A patent/KR20180095096A/ko not_active Ceased
- 2012-04-27 KR KR1020197008907A patent/KR20190037359A/ko not_active Ceased
- 2012-04-27 KR KR1020137031028A patent/KR20140043078A/ko not_active Ceased
- 2012-04-27 KR KR1020207011211A patent/KR20200043534A/ko not_active Ceased
- 2012-04-27 WO PCT/US2012/035547 patent/WO2012149389A2/en not_active Ceased
- 2012-04-27 CN CN201280027349.3A patent/CN103974712A/zh active Pending
- 2012-04-27 AU AU2012249397A patent/AU2012249397B2/en not_active Ceased
- 2012-04-27 US US14/114,376 patent/US20140107037A1/en not_active Abandoned
- 2012-04-27 BR BR112013027554A patent/BR112013027554A2/pt not_active Application Discontinuation
-
2016
- 2016-04-14 US US15/098,985 patent/US20170049845A1/en not_active Abandoned
-
2018
- 2018-10-23 US US16/168,242 patent/US20190209642A1/en not_active Abandoned
-
2019
- 2019-01-14 HK HK19100591.2A patent/HK1258231A1/zh unknown
-
2020
- 2020-05-05 US US16/867,324 patent/US20210169964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014520072A (ja) | 2014-08-21 |
| CA2834286A1 (en) | 2012-11-01 |
| US20140107037A1 (en) | 2014-04-17 |
| US20190209642A1 (en) | 2019-07-11 |
| CN108283712A (zh) | 2018-07-17 |
| EA201391581A1 (ru) | 2014-05-30 |
| MX2013012526A (es) | 2014-04-16 |
| EP2701721A4 (en) | 2015-12-16 |
| KR20200043534A (ko) | 2020-04-27 |
| EA201790653A1 (ru) | 2017-07-31 |
| BR112013027554A2 (pt) | 2016-09-06 |
| KR20180095096A (ko) | 2018-08-24 |
| HK1258231A1 (zh) | 2019-11-08 |
| WO2012149389A2 (en) | 2012-11-01 |
| US20170049845A1 (en) | 2017-02-23 |
| KR20190037359A (ko) | 2019-04-05 |
| AU2012249397A1 (en) | 2013-11-07 |
| JP6035326B2 (ja) | 2016-11-30 |
| EP3679931A3 (en) | 2020-10-14 |
| SG10202010665YA (en) | 2020-11-27 |
| WO2012149389A3 (en) | 2014-05-08 |
| EP2701721A2 (en) | 2014-03-05 |
| US20210169964A1 (en) | 2021-06-10 |
| KR20140043078A (ko) | 2014-04-08 |
| CN103974712A (zh) | 2014-08-06 |
| EP3679931A2 (en) | 2020-07-15 |
| AU2012249397B2 (en) | 2017-03-30 |
| EA029999B1 (ru) | 2018-06-29 |
| MX357761B (es) | 2018-07-23 |
| KR20210046843A (ko) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210169964A1 (en) | Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders | |
| EP2667715B1 (en) | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid | |
| EP3024463B1 (en) | Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | |
| CN103270022B (zh) | 神经营养蛋白受体激动剂及其作为药物的应用 | |
| Luo et al. | A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer’s disease | |
| CN108024976A (zh) | 阿米替林用于阻断大脑半通道的用途和用于增强其体内作用的方法 | |
| Pergolizzi et al. | The sigma enigma: A narrative review of sigma receptors | |
| WO2016083809A1 (en) | Neurodegenerative disorders | |
| JP2024097004A (ja) | 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用 | |
| WO2022215080A1 (en) | A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders | |
| HK1247847A1 (zh) | 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 | |
| CA2828831C (en) | Compounds and methods for the treatment of pain and other disorders | |
| CN115209908A (zh) | 具有神经保护、免疫调节、抗炎和抗微生物活性的基于蛋白质的药学组合物 | |
| JP2003508512A (ja) | 非ペプチド性サイクロフィリン結合化合物とその用途 | |
| EP1506776B1 (de) | Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen | |
| CN110719779A (zh) | 包含非外消旋比例的(r)-地来西坦(1)和(s)-地来西坦(2)的协同组合物 | |
| HK40034037A (en) | Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders | |
| JP2025514192A (ja) | 神経障害の治療 | |
| CN117479931A (zh) | 用于治疗孤独症谱系障碍(asd)的方法 | |
| JP2022529742A (ja) | 神経修復方法 | |
| KR20190095961A (ko) | Snap25 안티센스 올리고뉴클레오타이드 | |
| CA2968933C (en) | Peptides for use in neurodegenerative disorders | |
| US20190351006A1 (en) | Methods of administration of nmda receptor agonists | |
| KR20250171396A (ko) | 신경계 질환, 근육계 질환 및 증식성 질환 치료를 위한 메트포르민과 라파마이신의 병용 | |
| DE102007059924A1 (de) | Allel- und Isotyp-spezifische Intervention an mit Autoimmunerkrankungen assoziierten MHC-Klasse-II-Molekülen durch Peptide |